MétaCan
Menu
Back to cohort
Record W4246240489 · doi:10.1093/ijnp/pyw044.594

PT594. Placebo effects in Alzheimer Disease: analysis of the CATIE-AD data

2016· article· en· W4246240489 on OpenAlexaff
Chisa Ozawa, Takefumi Suzuki, Taishiro Kishimoto, Kazunari Yoshida, Nobuhiro Nagai, Ai Ohtani, Aki Endo, Masaru Mimura, Hiroyuki Uchida

Bibliographic record

VenueThe International Journal of Neuropsychopharmacology · 2016
Typearticle
Languageen
FieldNeuroscience
TopicPain Management and Placebo Effect
Canadian institutionsCentre for Addiction and Mental Health
Fundersnot available
KeywordsPlaceboDiseaseAlzheimer's diseaseMedicineInternal medicinePathologyAlternative medicine

Abstract

fetched live from OpenAlex

Abstract Background: Differences in symptom trajectories of behavioral and psychological symptoms with dementia (BPSD) between placebo and active drug responders have not been investigated. Additionally, ideal criteria for screening of potential placebo responders in a placebo lead-in phase in clinical trials for BPSD remain unknown. Methods: The data of 371 patients with Alzheimer disease (DSM-IV) in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness for Alzheimer disease (The CATIE-AD) were analyzed. The patients were randomly assigned to treatment with olanzapine, quetiapine, risperidone, or placebo in a double-blind condition. Trajectories of Brief Psychiatric Rating Scale (BPRS) total scores were compared between placebo and active drug responders (i.e. those who achieved a ≥25% BPRS total score reduction). Prediction performance of binary classification in improvement at week 2 for placebo response at week 8 was examined; sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the consecutive cut-off points in increments of 5% between 5% and 25% in the BPRS total score reduction at week 2 were calculated. Results: There were no significantly differences in symptom trajectories between placebo and drug groups. The cut-off of 10% at week 2 presented with the highest precision of 0.66 with sensitivity, NPV, specificity, and PPV of 0.53, 0.65, 0.77, and 0.68, respectively. Conclusion: Symptom trajectories of BPSD in responders follow a similar pattern irrespective of treatment modalities. The 10% cut-off at week 2 seems robust for the prediction of subsequent placebo response at week 8, which may need to be considered in future clinical trials to reduce failure trials for BPSD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.037

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.009
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.359
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractno

Explore more

Same venueThe International Journal of NeuropsychopharmacologySame topicPain Management and Placebo EffectFrench-language works237,207